Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma.

Hong A, Moriceau G, Sun L, Lomeli S, Piva M, Damoiseaux R, Holmen SL, Sharpless NE, Hugo W, Lo RS.

Cancer Discov. 2018 Jan;8(1):74-93. doi: 10.1158/2159-8290.CD-17-0682. Epub 2017 Sep 18.

PMID:
28923912
2.

Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation.

Song C, Piva M, Sun L, Hong A, Moriceau G, Kong X, Zhang H, Lomeli S, Qian J, Yu CC, Damoiseaux R, Kelley MC, Dahlman KB, Scumpia PO, Sosman JA, Johnson DB, Ribas A, Hugo W, Lo RS.

Cancer Discov. 2017 Nov;7(11):1248-1265. doi: 10.1158/2159-8290.CD-17-0401. Epub 2017 Sep 1.

3.

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.

Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang X, Parisi G, Saus CP, Torrejon DY, Graeber TG, Comin-Anduix B, Hu-Lieskovan S, Damoiseaux R, Lo RS, Ribas A.

Cell Rep. 2017 May 9;19(6):1189-1201. doi: 10.1016/j.celrep.2017.04.031.

4.

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS.

Cell. 2017 Jan 26;168(3):542. doi: 10.1016/j.cell.2017.01.010. No abstract available.

5.

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.

Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W, Sandoval S, Torrejon DY, Palaskas N, Rodriguez GA, Parisi G, Azhdam A, Chmielowski B, Cherry G, Seja E, Berent-Maoz B, Shintaku IP, Le DT, Pardoll DM, Diaz LA Jr, Tumeh PC, Graeber TG, Lo RS, Comin-Anduix B, Ribas A.

Cancer Discov. 2017 Feb;7(2):188-201. doi: 10.1158/2159-8290.CD-16-1223. Epub 2016 Nov 30.

6.

JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma.

Titz B, Lomova A, Le A, Hugo W, Kong X, Ten Hoeve J, Friedman M, Shi H, Moriceau G, Song C, Hong A, Atefi M, Li R, Komisopoulou E, Ribas A, Lo RS, Graeber TG.

Cell Discov. 2016 Sep 6;2:16028. doi: 10.1038/celldisc.2016.28. eCollection 2016.

7.

Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation.

Pan M, Reid MA, Lowman XH, Kulkarni RP, Tran TQ, Liu X, Yang Y, Hernandez-Davies JE, Rosales KK, Li H, Hugo W, Song C, Xu X, Schones DE, Ann DK, Gradinaru V, Lo RS, Locasale JW, Kong M.

Nat Cell Biol. 2016 Oct;18(10):1090-101. doi: 10.1038/ncb3410. Epub 2016 Sep 12.

8.

Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors.

Escuin-Ordinas H, Li S, Xie MW, Sun L, Hugo W, Huang RR, Jiao J, de-Faria FM, Realegeno S, Krystofinski P, Azhdam A, Komenan SM, Atefi M, Comin-Anduix B, Pellegrini M, Cochran AJ, Modlin RL, Herschman HR, Lo RS, McBride WH, Segura T, Ribas A.

Nat Commun. 2016 Aug 1;7:12348. doi: 10.1038/ncomms12348.

9.

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher TN, Lo RS, Ribas A.

N Engl J Med. 2016 Sep 1;375(9):819-29. doi: 10.1056/NEJMoa1604958. Epub 2016 Jul 13.

10.

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS.

Cell. 2016 Mar 24;165(1):35-44. doi: 10.1016/j.cell.2016.02.065. Epub 2016 Mar 17. Erratum in: Cell. 2017 Jan 26;168(3):542.

11.

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.

Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, Rizos H, Sucker A, Scolyer RA, Gutzmer R, Gogas H, Kefford RF, Thompson JF, Becker JC, Berking C, Egberts F, Loquai C, Goldinger SM, Pupo GM, Hugo W, Kong X, Garraway LA, Sosman JA, Ribas A, Lo RS, Long GV, Schadendorf D.

Eur J Cancer. 2015 Dec;51(18):2792-9. doi: 10.1016/j.ejca.2015.08.022. Epub 2015 Nov 19.

12.

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.

Hugo W, Shi H, Sun L, Piva M, Song C, Kong X, Moriceau G, Hong A, Dahlman KB, Johnson DB, Sosman JA, Ribas A, Lo RS.

Cell. 2015 Sep 10;162(6):1271-85. doi: 10.1016/j.cell.2015.07.061.

13.

Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.

Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC, Koya RC, Samatar AA, Khanlou N, Braun J, Ruchalski K, Seifert H, Larkin J, Dahlman KB, Johnson DB, Algazi A, Sosman JA, Ribas A, Lo RS.

Cancer Cell. 2015 Feb 9;27(2):240-56. doi: 10.1016/j.ccell.2014.11.018. Epub 2015 Jan 15.

14.

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.

M├╝ller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, Kong X, Possik PA, Cornelissen-Steijger PD, Geukes Foppen MH, Kemper K, Goding CR, McDermott U, Blank C, Haanen J, Graeber TG, Ribas A, Lo RS, Peeper DS.

Nat Commun. 2014 Dec 15;5:5712. doi: 10.1038/ncomms6712.

15.

Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors.

Marusiak AA, Edwards ZC, Hugo W, Trotter EW, Girotti MR, Stephenson NL, Kong X, Gartside MG, Fawdar S, Hudson A, Breitwieser W, Hayward NK, Marais R, Lo RS, Brognard J.

Nat Commun. 2014 May 22;5:3901. doi: 10.1038/ncomms4901.

16.

Stringent DDI-based prediction of H. sapiens-M. tuberculosis H37Rv protein-protein interactions.

Zhou H, Rezaei J, Hugo W, Gao S, Jin J, Fan M, Yong CH, Wozniak M, Wong L.

BMC Syst Biol. 2013;7 Suppl 6:S6. doi: 10.1186/1752-0509-7-S6-S6. Epub 2013 Dec 13.

17.

Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.

Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadige MR, Rao A, Sheppard KE, Hugo W, Pupo GM, Pearson RB, McGee SL, Long GV, Scolyer RA, Rizos H, Lo RS, Cullinane C, Ayer DE, Ribas A, Johnstone RW, Hicks RJ, McArthur GA.

Cancer Discov. 2014 Apr;4(4):423-33. doi: 10.1158/2159-8290.CD-13-0440. Epub 2014 Jan 27.

18.

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS.

Cancer Discov. 2014 Jan;4(1):80-93. doi: 10.1158/2159-8290.CD-13-0642. Epub 2013 Nov 21.

19.

A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.

Shi H, Hong A, Kong X, Koya RC, Song C, Moriceau G, Hugo W, Yu CC, Ng C, Chodon T, Scolyer RA, Kefford RF, Ribas A, Long GV, Lo RS.

Cancer Discov. 2014 Jan;4(1):69-79. doi: 10.1158/2159-8290.CD-13-0279. Epub 2013 Nov 21.

20.

Simultaneously learning DNA motif along with its position and sequence rank preferences through expectation maximization algorithm.

Zhang Z, Chang CW, Hugo W, Cheung E, Sung WK.

J Comput Biol. 2013 Mar;20(3):237-48. doi: 10.1089/cmb.2012.0233.

PMID:
23461573
21.

Discovering interacting domains and motifs in protein-protein interactions.

Hugo W, Sung WK, Ng SK.

Methods Mol Biol. 2013;939:9-20. doi: 10.1007/978-1-62703-107-3_2.

PMID:
23192537
22.

D-SLIMMER: domain-SLiM interaction motifs miner for sequence based protein-protein interaction data.

Hugo W, Ng SK, Sung WK.

J Proteome Res. 2011 Dec 2;10(12):5285-95. doi: 10.1021/pr200312e. Epub 2011 Nov 1.

PMID:
22004555
23.

SLiM on Diet: finding short linear motifs on domain interaction interfaces in Protein Data Bank.

Hugo W, Song F, Aung Z, Ng SK, Sung WK.

Bioinformatics. 2010 Apr 15;26(8):1036-42. doi: 10.1093/bioinformatics/btq065. Epub 2010 Feb 18.

PMID:
20167627
24.

A probabilistic graph-theoretic approach to integrate multiple predictions for the protein-protein subnetwork prediction challenge.

Chua HN, Hugo W, Liu G, Li X, Wong L, Ng SK.

Ann N Y Acad Sci. 2009 Mar;1158:224-33. doi: 10.1111/j.1749-6632.2008.03760.x.

PMID:
19348644
25.

A correlated motif approach for finding short linear motifs from protein interaction networks.

Tan SH, Hugo W, Sung WK, Ng SK.

BMC Bioinformatics. 2006 Nov 16;7:502.

26.

Antimicrobial activity and action of silver.

Russell AD, Hugo WB.

Prog Med Chem. 1994;31:351-70. Review. No abstract available.

PMID:
8029478
27.
28.

A brief history of heat and chemical preservation and disinfection.

Hugo WB.

J Appl Bacteriol. 1991 Jul;71(1):9-18. No abstract available.

PMID:
1894581
29.

Preservative activity in diluted corticosteroid creams.

Hugo WB, Denyer SP, York HL, Tucker JD.

J Hosp Infect. 1984 Sep;5(3):329-33.

PMID:
6208253
30.

A note on the effect of dilution and temperature on the bactericidal activity of potassium sorbate.

Lusher P, Denyer SP, Hugo WB.

J Appl Bacteriol. 1984 Aug;57(1):179-81.

PMID:
6490561
31.

Pseudomonas cepacia as contaminant and infective agent.

Pallent LJ, Hugo WB, Grant DJ, Davies A.

J Hosp Infect. 1983 Mar;4(1):9-13. No abstract available.

PMID:
6190894
33.

Early studies in the evaluation of disinfectants.

Hugo WB.

J Antimicrob Chemother. 1978 Nov;4(6):489-94. No abstract available.

PMID:
361678
34.
35.
36.

Cell composition and drug resistance in Escherichia coli.

Hugo WB, Ellis JO.

Microbios. 1978;21(85-86):135-52.

PMID:
221791
37.

The mode of action of tetradecyltrimethyl ammonium bromide (CTAB) on Staphylococcus aureus [proceedings].

Denyer SP, Hugo WB.

J Pharm Pharmacol. 1977 Dec;29 Suppl:66P. No abstract available.

PMID:
22699
38.

Proceedings: The effect of some antibacterial agents on proton flux across the membrane of Clostridium welchii.

Daltrey DC, Hugo WB.

J Pharm Pharmacol. 1974 Dec;26 Suppl:99P. No abstract available.

PMID:
4156784
39.

Studies on the mode of action of 4-ethylphenol on Escherichia coli.

Hugo WB, Bowen JG.

Microbios. 1973 Nov-Dec;8(31):189-97. No abstract available.

PMID:
4589868
41.
45.

The leakage of cations and amino acids from Staphylococcus aureus exposed to moist heat, phenol and dinitrophenol.

Allwood MC, Hugo WB.

J Appl Bacteriol. 1971 Jun;34(2):369-75. No abstract available.

PMID:
4939270
46.

Lipid depletion of bacteria induced by biotin deficiency and its relation to resistance to antibacterial agents.

Hugo WB, Bowen JG, Davidson JR.

J Pharm Pharmacol. 1971 Jan;23(1):69-70. No abstract available.

PMID:
4395898
47.

An evaluation of the activity of commercial cellulolytic and pectolytic enzymes.

Hugo WB, Eranil-Toktay DM.

Pharm Acta Helv. 1970 Aug;45(8):480-5. No abstract available.

PMID:
5494127
48.

The use of enzymes in the preparation of vegetable drug extracts.

Hugo WB, Eranil-Toktay DM.

Pharm Acta Helv. 1969 Sep;44(9):575-8. No abstract available.

PMID:
5821947
49.

Mode of action of the antibacterial compound dequalinium acetate.

Hugo WB, Frier M.

Appl Microbiol. 1969 Jan;17(1):118-27.

50.

Cellular lipid and the anti-staphylococcal activity of phenols.

Hugo WB, Franklin I.

J Gen Microbiol. 1968 Mar;50(3):Suppl:2-3. No abstract available.

PMID:
5652080

Supplemental Content

Support Center